Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Panel Approves Additional Shipment of Kaketsuken’s Venilon, Novact
November 20, 2015
- Viekirax Price, Peak Sales Forecast Called into Question
November 19, 2015
- Chuikyo OKs Viekirax, Other Drugs for NHI Price Listing on Nov. 26
November 19, 2015
- Chuikyo Approves Listing of Temcell and HeartSheet, First Two Regenerative Medicine Products
November 19, 2015
- AbbVie’s Hep C Drug Viekirax Priced at 53,000 Yen Daily vs. Harvoni’s 80,000 Yen
November 18, 2015
- MHLW Cautions against Reference Pricing, Says Impact on Pharmas Would Be Huge
November 18, 2015
- Research-Driven Drug Makers Should Collaborate with Startups, Academia: MHLW Official
November 17, 2015
- PAFSC’s 2nd Committee to Review Lung Cancer Indication for Opdivo on Nov. 30
November 17, 2015
- PAFSC 1st Committee to Discuss Japan’s First PCSK9 Inhibitor on Nov. 27
November 16, 2015
- Novartis Japan Told to Improve Business over Delayed Reporting of Nearly 5,500 ADRs
November 16, 2015
- Business Improvement Order Issued to Novartis Japan
November 13, 2015
- “We Want to Avoid a Market Price Survey” Ahead of NHI Price Revision in FY2017: MHLW Official
November 13, 2015
- Re-Pricing of “Huge Seller” Drugs Seen Inevitable Despite Industry Opposition
November 12, 2015
- Chuikyo Leaning toward Continuing Innovation Premium for On-Patent Drugs
November 12, 2015
- Chuikyo Subcommittee Broadly OKs Price Maintenance Rule for Essential Drugs
November 12, 2015
- Financial Impact of New Drug Development Premium in FY2014 Revision Totaled 79 Billion Yen
November 12, 2015
- MHLW Floats Incentive for Hospital-Pharmacy Collaboration to Reduce Drugs Prescribed to Elderly
November 10, 2015
- JMA Reps Express Opposition to Expansion of Divided Dispensing of Long-Term Prescriptions at Chuikyo
November 10, 2015
- Novartis Fails to Report Nearly 5,500 Side Effect Cases, Biz Improvement Order Likely This Month
November 10, 2015
- MHLW Pitches Generic Incentive for In-Hospital Dispensing; Quality Worries Still Simmering at Chuikyo
November 9, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…